Mumbai, India – Sun Pharma shares dropped more than 3% to ₹1,738 on Thursday after the US Food and Drug Administration (FDA) flagged its Baska manufacturing facility, assigning it an Official Action Indicated (OAI) status following a recent inspection.
Market Performance
Thursday saw Sun Pharma stocks dip, reflecting investor caution amid regulatory developments. The broader Indian stock market remained mixed, but the pharma sector drew attention due to the FDA update and the company's ongoing operational performance.
Main News: US FDA Inspection
According to an official exchange filing, the FDA conducted a thorough inspection of Sun Pharma’s Baska facility between September 8 and 19, 2025. Following the inspection, the regulator classified the plant under OAI status—a designation highlighting areas requiring corrective action.
Sun Pharma stated that it will continue to manufacture and supply approved products to the US market and actively work with the FDA to achieve full compliance.
Company Financials: Q2 FY26 Highlights
Sun Pharma reported a strong quarterly performance despite the regulatory concerns:
- Consolidated Net Profit: ₹3,118 crore, up 2.5% YoY from ₹3,040 crore
- Revenue from Operations: ₹14,478 crore, up 9% YoY from ₹13,291 crore
- EBITDA: ₹4,527 crore, up 15% YoY from ₹3,939 crore
- EBITDA Margin: Improved to 31.2% from 29.6% in the same quarter last year
The results indicate a healthy operational performance, driven by robust sales in domestic and international markets.
Summary
Sun Pharma’s share price experienced a short-term decline following the FDA classification of its Baska facility. However, the company continues to supply products from the plant and is taking steps to achieve full regulatory compliance. Meanwhile, its Q2 FY26 financials reflect strong revenue growth and improving profitability, highlighting the resilience of its core business despite regulatory scrutiny.
Easy & quick
Leave A Comment?